secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0000950170-25-086142
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen terminates prior HiFiBiO license deal, licenses anti-CCR8 and anti-Gal-9 assets
--------------------------------------------------------------------------------

- Terminated Exclusive License and Option Agreement with HiFiBiO dated June 2021, as amended Feb 2024.
- Licensed anti-CCR8 (FG-3175) and anti-Gal-9 (FG-3165) intellectual property to HiFiBiO.
- Eligible for mid single-digit to low double-digit share of HiFiBiO's sublicense revenues and low double-digit share of commercial royalties.
- If HiFiBiO commercializes either asset, FibroGen receives single-digit royalties on worldwide net sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017025086142/0000950170-25-086142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017025086142/fgen-20250612.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-086142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer